Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants

Joseph D Symonds, Katherine S Elliott, Jay Shetty, Martin Armstrong, Andreas Brunklaus, Ioana Cutcutache, Louise A Diver, Liam Dorris, Sarah Gardiner, Alice Jollands, Shelagh Joss, Martin Kirkpatrick, Ailsa McLellan, Stewart MacLeod, Mary O'Regan, Matthew Page, Elizabeth Pilley, Daniela T Pilz, Elma Stephen, Kirsty Stewart, Houman Ashrafian, Julian C Knight, Sameer M Zuberi, Joseph D Symonds, Katherine S Elliott, Jay Shetty, Martin Armstrong, Andreas Brunklaus, Ioana Cutcutache, Louise A Diver, Liam Dorris, Sarah Gardiner, Alice Jollands, Shelagh Joss, Martin Kirkpatrick, Ailsa McLellan, Stewart MacLeod, Mary O'Regan, Matthew Page, Elizabeth Pilley, Daniela T Pilz, Elma Stephen, Kirsty Stewart, Houman Ashrafian, Julian C Knight, Sameer M Zuberi

Abstract

Epilepsies of early childhood are frequently resistant to therapy and often associated with cognitive and behavioural comorbidity. Aetiology focused precision medicine, notably gene-based therapies, may prevent seizures and comorbidities. Epidemiological data utilizing modern diagnostic techniques including whole genome sequencing and neuroimaging can inform diagnostic strategies and therapeutic trials. We present a 3-year, multicentre prospective cohort study, involving all children under 3 years of age in Scotland presenting with epilepsies. We used two independent sources for case identification: clinical reporting and EEG record review. Capture-recapture methodology was then used to improve the accuracy of incidence estimates. Socio-demographic and clinical details were obtained at presentation, and 24 months later. Children were extensively investigated for aetiology. Whole genome sequencing was offered for all patients with drug-resistant epilepsy for whom no aetiology could yet be identified. Multivariate logistic regression modelling was used to determine associations between clinical features, aetiology, and outcome. Three hundred and ninety children were recruited over 3 years. The adjusted incidence of epilepsies presenting in the first 3 years of life was 239 per 100 000 live births [95% confidence interval (CI) 216-263]. There was a socio-economic gradient to incidence, with a significantly higher incidence in the most deprived quintile (301 per 100 000 live births, 95% CI 251-357) compared with the least deprived quintile (182 per 100 000 live births, 95% CI 139-233), χ2 odds ratio = 1.7 (95% CI 1.3-2.2). The relationship between deprivation and incidence was only observed in the group without identified aetiology, suggesting that populations living in higher deprivation areas have greater multifactorial risk for epilepsy. Aetiology was determined in 54% of children, and epilepsy syndrome was classified in 54%. Thirty-one per cent had an identified genetic cause for their epilepsy. We present novel data on the aetiological spectrum of the most commonly presenting epilepsies of early childhood. Twenty-four months after presentation, 36% of children had drug-resistant epilepsy (DRE), and 49% had global developmental delay (GDD). Identification of an aetiology was the strongest determinant of both DRE and GDD. Aetiology was determined in 82% of those with DRE, and 75% of those with GDD. In young children with epilepsy, genetic testing should be prioritized as it has the highest yield of any investigation and is most likely to inform precision therapy and prognosis. Epilepsies in early childhood are 30% more common than previously reported. Epilepsies of undetermined aetiology present more frequently in deprived communities. This likely reflects increased multifactorial risk within these populations.

Keywords: epidemiology; epilepsy; genetics; incidence; precision.

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Figures

Figure 1 Incidence by age of presentation.
Figure 1 Incidence by age of presentation.
(A) Incidence of epilepsies by age of presentation, per 100 000 live births. (B) Cumulative incidence of epilepsies by age of presentation, per 100 000 live births.
Figure 2 Incidence and deprivation.
Figure 2 Incidence and deprivation.
(A) Incidence of epilepsies by SIMD category, per 100 000 live births. (B) Incidence of epilepsies with aetiology by SIMD category, per 100 000 live births. (C) Incidence of epilepsies without aetiology by SIMD category, per 100 000 live births.
Figure 3
Figure 3
Diagnostic yield from investigations carried out before and after presentation with seizures. A 104 gene epilepsy panel provided the diagnosis for 39% of the total with aetiology, and for 63% of those whose investigations were initiated after presentation with seizures. Neuroimaging after presentation with seizures only provided an aetiological diagnosis in 9% of the total with aetiology.
Figure 4
Figure 4
Aetiological spectrum of the more common epilepsy syndromes of early childhood, showing the total yield from aetiological investigations for each epilepsy syndrome. DEE = developmental and epileptic encephalopathy.
Figure 5 Aetiology as the main driver…
Figure 5 Aetiology as the main driver of epilepsy severity and the key to effective treatment.
(A) Correlation network, demonstrating interrelationships between aetiology, age, seizure type, GDD and DRE. Thickness of arrow represents strength of relationship (Wald statistic on binomial regression model). Outcomes were strongly determined by aetiology. (B) Early identification of aetiology may allow prompt initiation of aetiology directed therapy and thereby improve outcomes.

References

    1. Fisher RS, Emde V, Boas W, et al.Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470–472.
    1. Fisher RS, Acevedo C, Arzimanoglou A, et al.A practical definition of epilepsy. Epilepsia. 2014;55(4):475–482.
    1. Oates S, Tang S, Rosch R, et al.Incorporating epilepsy genetics into clinical practice: A 360° evaluation. NPJ Genom Med. 2018;3:13.
    1. Devinsky O, Patel AD, Cross JH, et al.; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Eng J Med. 2018;378(20):1888–1897.
    1. Thiele EA, Marsh ED, French JA, et al.Cannabidiol in a patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–1096.
    1. Devinsky O, Cross JH, Laux L, et al.Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Eng J Med. 2017;376(21):2011–2019.
    1. Lagae L, Sullivan J, Knupp K, et al.Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A randomised, double-bind, placebo-controlled trial. Lancet. 2019;394(10216):2243–2254.
    1. Mesraoua B, Deleu D, Kullmann DM, et al.Novel therapies for epilepsy in the pipeline. Epilepsy Behav. 2019;97:282–290.
    1. Hauser WA, Annegers JF, Kurland LT.. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453–458.
    1. Wirrell E, Wong‐Kisiel L, Mandrekar J, Nickels K.. Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: A retrospective, population‐based study. Epilepsia. 2012;53(9):1563–1569.
    1. Berg AT, Langfitt JT, Testa FM, et al.Global cognitive function in children with epilepsy: A community-based study. Epilepsia. 2008;49(4):608–614.
    1. Jennum P, Pickering L, Christensen J, Ibsen R, Kjellberg J.. Morbidity and mortality of childhood-and adolescent-onset epilepsy: A controlled national study. Epilepsy Behav. 2017;66:80–85.
    1. National Records of Scotland. Accessed 11 March 2020.
    1. Kwan P, Arzimanoglou A, Berg AT, et al.Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2009;51(6):1069–1077.
    1. McDonald L, Rennie A, Tolmie J, Galloway P, McWilliam R.. Investigation of global developmental delay. Arch Dis Child. 2006;91(8):701–705.
    1. Scheffer IE, Berkovic S, Capovilla G, et al.ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521.
    1. Symonds JD, Zuberi SM, Stewart K, et al.Incidence and phenotypes of childhood-onset genetic epilepsies: A prospective population-based national cohort. Brain. 2019;142(8):2303–2317.
    1. Scottish Index of Multiple Deprivation. Accessed 11 March 2020.
    1. Pickrell WO, Lacey AS, Bodger OG, et al.Epilepsy and deprivation, a data linkage study. Epilepsia. 2015;56(4):585–591.
    1. Morgan CLI, Ahmed ZA, Kerr MP.. Social deprivation and prevalence of epilepsy and associated health usage. J Neurol Neurosurg Psychiatry. 2000;69(1):13–17.
    1. Huang LT. Early-life stress impacts the developing hippocampus and primes seizure occurrence: Cellular, molecular, and epigenetic mechanisms. Front Mol Neurosci. 2014;7:8.
    1. Johnson SB, Riis JL, Noble KG.. State of the Art Review: Poverty and the developing brain. Pediatrics. 2016;137(4):e20153075.
    1. Cassano PA, Koepsell TD, Farwell JR.. Risk of febrile seizures in childhood in relation to prenatal maternal cigarette smoking and alcohol intake. Am J Epidemiol. 1990;132(3):462–473.
    1. Lawder R, Whyte B, Wood R, Fischbacher C, Tappin DM.. Impact of maternal smoking on early childhood health: A retrospective cohort linked dataset analysis of 697 003 children born in Scotland 1997–2009. BMJ Open. 2019;9(3):e023213.
    1. Leu C, Stevelink R, Smith AW, et al.; Epi25 Consortium. Polygenic burden in focal and generalized epilepsies. Brain. 2019;142(11):3473–3481.
    1. Kurki MI, Saarentaus EC, Pietiläinen O, et al.Contribution of rare and common variants to intellectual disability in a sub-isolate of Northern Finland. Nat Commun. 2019;10(1):410.
    1. Saarentaus EC, Havulinna AS, Mars N, et al.Polygenic burden has broader impact on health, cognition, and socioeconomic outcomes than most rare and high-risk copy number variants. Mol Pscyhiatry. Published online 1 February 2021. doi:10.1038/s41380-021-01026-z
    1. Aaberg KM, Gunnes N, Bakken IJ, et al.Incidence and prevalence of childhood epilepsy: A nationwide cohort study. Pediatrics. 2017;139(5):e20163908.
    1. Gaily E, Lommi M, Lapatto R, Lehesjoki A.. Incidence and outcome of epilepsy syndromes with onset in the first year of life: A retrospective population-based study. Epilepsia. 2016;57(10):1594–1601.
    1. Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM.. Incidence of epilepsy in childhood and adolescence: A population-based study in Nova Scotia from 1977 to 1985. Epilepsia. 1996;37(1):19–23.
    1. Wirrell EC, Grossardt BR, Wong-Kisiel LCL, Nickels KC.. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: A population-based study. Epilepsy Res. 2011;95(1-2):110–118.
    1. Eltze CM, Chong WK, Cox T, et al.A population-based study of newly diagnosed epilepsy in infants. Epilepsia. 2013;54(3):437–445.
    1. Lindy AS, Stosser MB, Butler E, Downtain‐Pickersgill C, Shanmugham A, et al.Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia. 2018;59(5):1062–1071.
    1. Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C.. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain. 2015;138(Pt 12):3476–3495.
    1. Marini C, Conti V, Mei D, et al.PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraine. Neurology. 2012;79(21):2109–2114.
    1. O'Callaghan FJK, Edwards SW, Alber FD, et al.Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018;2(10):715–725.
    1. Symonds JD, McTague A.. Epilepsy and developmental disorders: Next generation sequencing in the clinic. Eur J Paed Neurol. 2020;24:15–23.
    1. Kearney H, Byrne S, Cavalleri GL, Delanty N.. Tackling epilepsy with high-definition precision medicine: a review. JAMA Neurology. 2019;76(9):1109–1116.
    1. de Lange IM, Boudewijn G, Sonsma AC, et al.Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018;59(6):1154–1165.
    1. Williams J, Steel C, Sharp GB, et al.Parental anxiety and quality of life in children with epilepsy. Epilepsy Beh. 2003;4(5):483–486.
    1. Lv R, Wu L, Jin L, et al.Depression, anxiety and quality of life in parents of children with epilepsy. Acta Neurol Scand. 2009;120(5):335–341.
    1. Brunklaus A, Dorris L, Zuberi SM.. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia. 2011;52(8):1476–1482.
    1. O'Callaghan FJK, Edwards SW, Alber FD, et al.; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16(1):33–42.
    1. Scoto M, Finkel R, Mercuri E, Muntoni F.. Genetic therapies for inherited neuromuscular diseases. Lancet Child Adolesc Health. 2018;2(8):600–609.

Source: PubMed

3
Iratkozz fel